Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
New Novartis: Our strategy
Deliver high-value medicines that alleviate society's greatest disease burdens
through technology leadership in R&D and novel access approaches
Our focus
5 core Therapeutic Areas¹
Cardiovascular, Immunology,
Neuroscience, Solid Tumors, Hematology
Our priorities
Accelerate growth
Deliver high-value
medicines (including
launch excellence)
Deliver returns
Embed
operational
excellence
2 + 3 technology platforms
Chemistry, Biotherapeutics
XRNA, Radioligand, Gene & Cell Therapy
4 priority geographies
US, China, Germany, Japan
1. Other TAs opportunistically.
Strengthen foundations
Unleash the power
of our people
Scale data science
and technology
Build trust with society
28 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation